New drug SHR-A1811 targets HER2-Positive cancers in early trial
NCT ID NCT04513223
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called SHR-A1811 in 101 people with advanced stomach or colorectal cancers that have a specific protein called HER2. The main goals were to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants had cancers that no longer responded to standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1811 (a targeted drug that attacks cancer cells with a specific protein called HER2)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced stomach or colorectal cancers that have the HER2 protein and have not responded to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 101 participants, so the main goals are safety and finding the right dose—not proving the drug works. The drug may cause side effects or fail to shrink tumors in later, larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a new drug combo revive Immunotherapy's power against resistant tumors?